© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Granisetron Hydrochloride traces its roots to the push for serious improvements in cancer treatment support. In the 1980s, many patients faced relentless nausea from chemotherapy, often leading to malnutrition and poor outcomes. Antiemetic drugs barely touched the surface until researchers zeroed in on the serotonin (5-HT3) receptor pathway. Glaxo, driving this research, synthesized granisetron to block these particular receptors in the gut and brain. Approval in the 1990s shifted care for cancer patients, providing smoother recovery paths after chemo. Since then, granisetron hasn't faded into medical history; it remains a steady backbone in clinical oncology.
Taking granisetron hydrochloride off the shelf, you find a white or almost white powder, not much different at first glance from any other pharmaceutical compound. Yet, hidden in those grains is a small molecule that resists breakdown in stomach acid, travels through the bloodstream, and does exactly what it is supposed to do—stop serotonin from wreaking havoc in the gut during chemo. Granisetron comes in tablets, injectables, and transdermal patches. The tablets sit well with adults and kids alike, offering a reliable course over days with minimal side effects compared to earlier antiemetics.
Granisetron hydrochloride, C18H25ClN4O, sits comfortably in the category of synthetic indazole derivatives. Crystalline and stable below room temperature, it holds well in light and air, which means pharmacists rarely worry about losses during handling. As a hydrochloride salt, it dissolves easily in water, boosting its suitability for injection or oral use. Its melting point comfortably above 290°C speaks to its stability. If you accidentally get some on your hand during prep, it feels chalky, not gritty or oily.
Each bottle or tablet pack tells a clear story. You’ll read dosage strength in milligrams, with routes of administration stamped on the label. Tablets often list 1 mg or 2 mg per piece. Injectables arrive in pre-measured vials with clear dilution instructions. Expiration dates and storage temperature limits appear in bold—between 20°C and 25°C is ideal. Safety seals protect contents from tampering, while batch numbers track every lot. Regulatory standards demand detailed pharmacopeial information, covering everything from particle size to water content. In medical practice, these labels help avoid mix-ups, speed up audits, and guarantee traceability in case of recalls.
Synthesizing granisetron hydrochloride involves precise steps, starting with indazole and working through a sequence of alkylation and heterocyclic reactions. Chemists employ strict control over reaction temperatures and solvents, using robust filtration and crystallization to isolate the pure hydrochloride salt. Purity checks with high-performance liquid chromatography ensure no contaminants sneak through. The process produces consistently pure, pharmaceutical-grade powder that needs no further treatment before compounding.
Granisetron itself resists many chemical changes, holding its active form under a range of conditions. Modification usually targets solubility or molecular delivery by creating salt forms or embedding granisetron in polymer matrices. Research teams exploring analogues tweak the indazole core, hoping for longer action or better bioavailability. Still, most chemists agree that the hydroxy and amine groups on granisetron resist breakdown, which explains its long shelf life and reliability.
Pharma shelves won't always use the same name for granisetron hydrochloride. You’ll see product names like Kytril, Sancuso (for transdermal patches), and the names of various generics across global markets. Chemical supply catalogs use names like N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride. Some textbooks shorthand it as “GRN” or “GS” for quick reference. These names create confusion in procurement or research ordering, so checking catalog numbers and chemical structure often saves costly mix-ups.
Working with granisetron hydrochloride calls for strict adherence to safety. Lab techs and pharmacists know it travels easily on skin and can irritate mucous membranes if mishandled. Gloved hands, eye protection, and fume hoods during clinical compounding remain standard. Manufacturing environments adopt GMP protocols, emphasizing cleanroom garb and air-filtration to block contamination. Transport packaging carries full hazard identification, pointing out proper disposal in case of spillage. Regular training covers not just handling, but also quick response to accidental exposure—as granisetron can cause contact dermatitis or headache in rare cases.
Oncology rules the list. Doctors prescribe granisetron hydrochloride for patients scheduled for major chemotherapies—especially those notorious for strong stomach upset. For many cancer centers, it shows up in pre-printed order sets, often paired with corticosteroids. Beyond oncology, granisetron comes into play after surgery, especially with procedures that risk severe postoperative nausea. Pediatric wards have turned to it for both chemotherapy and post-anesthesia nausea, and recent guidelines now highlight its lower risk of drowsiness or movement disorders compared to older drugs like metoclopramide. In emergency care, granisetron rescues patients from intractable vomiting when common options fail.
Ongoing work with granisetron hydrochloride pivots not just on new cancers but also unexplored uses. Clinical teams have investigated its impact on migraines and irritable bowel syndrome, yielding mixed but promising results. Trials keep looking for optimal delivery routes—like sustained-release patches and oral films—aimed at both improved convenience and patient compliance. Researchers constantly battle issues like emerging serotonin antagonist resistance and seek affordable ways to synthesize granisetron without environmental hazards. Cross-field collaborations look at combining granisetron with cannabinoids or NK-1 antagonists for even stronger anti-nausea effects.
Most granisetron toxicity research shows modest risks at therapeutic doses. In lab animals, very high amounts bring mild cardiac and CNS effects, with a wide safety margin for human use. Trials in pregnant models reveal no significant teratogenic effects, keeping it within the green zone for short-term clinical use when benefits outweigh risks. Yet, like many serotonin blockers, rare cases of serotonin syndrome pop up—especially when combined with selective serotonin reuptake inhibitors. Ongoing animal studies monitor long-term outcomes, with a sharp eye for subtle neurodevelopmental changes that might suggest late-onset complications.
Looking ahead, granisetron hydrochloride stands to benefit from new drug delivery technologies—think nanoparticle encapsulation or smart-release implants capable of weeks-long coverage without repeat dosing. Personalized medicine trends point toward tailored antiemetic therapy, where genetic tests predict which patients respond best to granisetron versus alternatives. Manufacturers aim to trim production waste and improve sustainability, with biocatalytic routes in synthesis under real consideration. Clinicians, meanwhile, hope for combination pills that blend granisetron with other support meds, shrinking the number of daily doses cancer patients must juggle. As healthcare emerges from the shadow of one-size-fits-all regimens, granisetron’s strong track record and room for innovation will keep it in high rotation at both bedside and research lab.
For people facing cancer treatment, nausea and vomiting can make an already tough journey even tougher. Granisetron Hydrochloride has become a bit of a cornerstone in the toolkit doctors turn to for relief. This drug blocks the action of serotonin, a chemical in the body that can trigger nausea after chemotherapy, radiation, or surgery. It’s not a magic solution, but many people find that the edge comes off their sickness enough to eat and move around again, which matters a lot during recovery.
My own friend battled through chemo a few years back. Every session, the feeling of nausea took over within hours, sometimes lasting for days. The first medications offered brought only slight relief. Switching to Granisetron Hydrochloride changed her experience—she managed a sandwich the next day, she chatted with her family, and spirits lifted. It doesn’t wipe nausea off the map for everyone, but patients getting major cancer treatments, or who react badly to anesthesia, often call it a lifeline.
The data stacks up behind this medicine. Clinical studies show Granisetron makes a real difference: during chemotherapy, over 60% of people saw their vomiting controlled for at least 24 hours after a dose. Few prescription drugs for nausea compare with this track record. Safety counts for a lot. Most folks feel minimal side effects—some might notice headaches or constipation, but severe problems, such as allergic reactions or changes to the heartbeat, show up rarely and usually in people with other health issues.
Getting medical care isn’t just about eradicating disease—it's about making life bearable while doing it. Granisetron Hydrochloride gives doctors and patients a fighting chance to hold on to daily routines. Even eating a light meal or staying hydrated during tough times can tip the scales toward recovery. The American Society of Clinical Oncology recommends using drugs like Granisetron for patients at high risk of severe nausea from chemotherapy, which shows how much clinical trust backs these options.
Insurance coverage often makes things complicated. Costs run high for brand-name versions of the drug, putting some people in a bind. Generics help, but only if local pharmacies stock them. Seeing loved ones forced to choose between paying for relief or skipping it always hits a nerve. Policy changes, better insurance terms for anti-nausea drugs, and increased availability of generic options could take off some pressure.
Questions keep popping up in research circles. Can combining Granisetron with other antiemetics do more for stubborn cases of nausea or vomiting? Personalized medicine will likely play a bigger role soon—genetic testing to see who responds best makes sense, given the variation in outcomes. Nurses and pharmacists have shared first-hand stories about teaching patients and caregivers to track side effects and to speak up quickly if something feels off. Health teams treating each case as unique, rather than one-size-fits-all, help people get the most from each dose.
Granisetron Hydrochloride works to reduce nausea and vomiting often linked to chemotherapy, radiation, or surgery. Doctors trust it because it blocks certain receptors in the body connected to the urge to vomit. Still, as with most strong medicines, it comes with its set of possible side effects. Patients experience these differently, but being prepared can help people and families manage them better.
Patients sometimes talk about headaches after taking granisetron. It happens enough to show up in most drug information leaflets. I remember caring for a family member recovering from chemotherapy. Feeling sick was tough enough, but spinning headaches from the medicine made things rougher. Over-the-counter painkillers dulled the edge, but relief varied from person to person. Some people also feel constipated. Doctors often suggest increasing water, eating more fiber, or, for severe constipation, recommending a gentle laxative. If bowel movements slow down and bring discomfort, it’s important to bring it up with the medical team.
Drowsiness shows up in some people, causing tiredness or brain fog. Those planning daily activities need to know that concentration can dip at odd times. Also, patients occasionally mention feeling dizzy, especially when standing up too quickly. Trying to move slower worked for us at home, but it took a few weeks to adjust. A few people report changes in how food tastes, less appetite, or mild stomach pain. These symptoms rarely last long, but during stressful treatment periods, even minor upsets make daily life harder. For elderly patients, dehydration and lost appetite can snowball if not caught early.
An allergic reaction can happen, though it’s rare. Hives, swelling in the face or throat, trouble breathing—these points suggest the need for emergency care, no hesitation. In decades of family health experiences, even one unexpected swelling taught us to call for an ambulance rather than wait. That speeds up treatment and can save lives.
Some doctors worry about changes in electrical signals in the heart, known as QT prolongation. These rhythms can cause palpitations, chest discomfort, or fainting. Granisetron tends to have fewer of these cases than older nausea drugs, but it’s something to talk through, especially in people with heart conditions. Anyone taking other medicines that affect heart rhythm should mention all prescriptions and supplements to the doctor or pharmacist. Blood tests keep checks on potassium and magnesium, as low levels add heart risks. One small slip in relay information can lead to confusion or missed early warning signs, making open conversation key.
For anyone worried about side effects, it helps to use a diary or app to track symptoms each day. Bring this info to medical appointments, and ask about anything odd. No one gains from hiding troubles out of politeness. Sometimes, changing the timing or dose of granisetron manages side effects. New research and doctor experience build the safest way forward. Clear answers, honest questions, and respect for each patient’s specifics make all the difference in treatment journeys.
Granisetron Hydrochloride enters the picture as a lifeline for people dealing with nausea and vomiting, often after chemotherapy, radiation, or surgery. This medication stands among the better-known antiemetic drugs, working by blocking certain signals in the brain that trigger nausea. Healthcare workers and families count on its reliable performance to keep patients comfortable in tough circumstances. I’ve seen firsthand how nausea can disrupt recovery, making it vital to get this medication’s use right.
Doctors offer Granisetron in two main forms: tablets taken by mouth and solutions for injection. Most folks recognize the convenience of a pill, but some situations demand something faster or for patients who can’t keep anything down. That’s where the injectable form comes into play. In hospitals, nurses might give granisetron through a standard injection into a vein, sometimes just before chemo starts. It’s nothing fancy, but it gets the drug working quickly.
Oral tablets often suit outpatients. I’ve seen care teams stress the need to swallow the pill whole with water, without crushing or chewing it. Sometimes, doctors tell patients to start dosing an hour before chemotherapy. This timing isn’t random. Getting granisetron into the bloodstream before the body figures out what’s coming can take the edge off the nausea.
Intravenous dosing usually takes place in a clinic or hospital. Trained staff draw the proper dose and inject it slowly into a vein, often in the hand or arm. If you’re on the receiving end, mentioning any stinging or burning during the injection matters. Nobody wants a mistake or complication, especially at such a vulnerable moment.
Everyone involved—doctors, nurses, patients—keeps a few safety tips close. Allergies matter, especially if the patient reacts to any similar medications. I once saw a patient catch a mild rash on the neck, and the team switched solutions fast, avoiding bigger problems.
Granisetron doesn’t usually play well with some other drugs. Telling every care provider about all medicines in use, even herbal supplements, builds a safer environment for all involved. Watching out for side effects such as headaches or constipation sets a good foundation for catching rare but more serious problems like irregular heartbeat. People sometimes overlook these signs, blaming chemo or illness, but smart vigilance matters.
Clear, honest conversation between patients and medical teams helps catch issues early. Patients do best keeping track of doses and reporting anything unusual. In outpatient settings, written instructions and regular check-ins reduce the risk of missed doses or confused schedules. Family or caregivers help by creating reminders and checking that the medication is taken properly.
Granisetron Hydrochloride works best in a partnership between well-informed patients and thorough professionals. Solid fact-based education, visible labels, and thoughtful monitoring anchor its role in modern care, helping people push through some tough days with fewer setbacks.
Doctors prescribe Granisetron Hydrochloride to tackle nausea and vomiting, especially in people going through chemotherapy. For anyone pregnant or nursing, questions about safety naturally come to mind. Many folks, myself included, have sat in hospital rooms, holding someone’s hand, looking for solid, honest answers about what will help—without adding new risks.
Granisetron Hydrochloride works by blocking serotonin, which plays a big role in triggering nausea. Because of how targeted it is, Granisetron doesn't knock out other systems or cause grogginess like some older treatments. Still, just because it helps manage symptoms well doesn’t give it a free pass for everyone, especially expectant mothers and infants.
Few studies have closely tracked large groups of pregnant women who took Granisetron. Animal testing trails offer some clues—no clear sign of birth defects in rats or rabbits at standard doses. Yet, animals are not people, and differences matter at this level. Human data stays pretty thin, coming mostly from case reports and small observational studies. These pockets of evidence haven’t linked Granisetron to major pregnancy complications—miscarriage, birth defects, or low birth weight aren't more common in those reports. Still, doctors hesitate to make sweeping promises.
Everyone in healthcare stresses the same thing: balance the risks and benefits. Severe vomiting during pregnancy, such as with hyperemesis gravidarum, can leave mothers dehydrated and malnourished. Sometimes the risk of not treating outweighs the mystery of what a medicine might bring.
The big unknown hangs over breastfeeding: does Granisetron get into breast milk, and if so, what happens next? Research hasn't provided a clear chemical trail from mom to baby through milk. Based on its chemical profile—low molecular weight, moderate fat solubility—traces may slip into milk, but nobody has clocked real numbers in human trials. Infants have delicate systems, and even tiny amounts can spark bigger reactions. With that in mind, experts usually suggest pausing breastfeeding or finding a safer alternative, unless there is no other practical option.
Clear answers don’t always exist, especially in health. Granisetron won’t make every “safe” medication list for pregnant or nursing mothers. The FDA places it in Category B, reflecting a cautious hope based on animal data, not hard assurances from large human studies.
Physicians use a shared decision-making approach, discussing options one-on-one. They often lean toward older, better-studied drugs such as doxylamine, vitamin B6, or ondansetron when possible, unless severe nausea means stronger help is needed. Pharmacists are key allies here, helping spot drug interactions or warn about less obvious side effects.
If you or someone you know faces the bold, sometimes scary questions about nausea treatment during these sensitive stages, real dialogue with healthcare professionals makes all the difference. The best path weighs risks, respects the unknowns, and never loses sight of the patient at the heart of it all.
Granisetron hydrochloride does a solid job for people dealing with chemotherapy-induced nausea or surgical recovery. Doctors often hand it out in hospitals and clinics. But the medicine cabinet tends to fill up fast, especially for those managing more than one condition. Nobody wants a surprise from a drug interaction. So let’s dig in—how does granisetron hydrochloride get along with other meds?
This medication mainly acts as a selective serotonin 5-HT3 receptor antagonist, easing nausea by blocking serotonin in the body. That may sound technical, but it keeps you from feeling relentlessly sick when your system already has enough to handle. The trouble comes when serotonin-targeting drugs pile up. For example, anti-depressants like fluoxetine (Prozac), sertraline (Zoloft), or even over-the-counter cold remedies with dextromethorphan all nudge serotonin around. Add granisetron, and serotonin can build up. Too much can bring on headaches, confusion, increased heart rate, or in severe cases, serotonin syndrome. In the real world, this matters because more people are taking both chemo and antidepressants, especially as survivorship rates go up.
Nothing gets a pharmacist’s attention like medications with a reputation for prolonging the QT interval on an ECG. Granisetron hydrochloride isn’t usually the first drug people blame, but it has the potential to stretch that interval. Add in a medicine like amiodarone, methadone, or even certain antibiotics like erythromycin, and the risk for irregular heart rhythms increases. For patients with a history of cardiac disease or folks over 65, monitoring matters more than ever. Even grapefruit or other foods that alter drug metabolism can shift risk upwards, surprising those relying on routine for their peace of mind.
From my own time helping folks navigate medicine lists, the best shield against harm comes from open conversations. It’s easy for anyone to miss a new drug added by a different doctor, especially if all those bottles start to look alike. Bring an up-to-date med list, including any supplements, to every appointment. Pharmacists will often spot a red flag before it becomes a crisis. Most people like using a single pharmacy for that reason—that person behind the counter remembers you, and your prescriptions. Even family members can help catch problems if the patient has memory trouble.
For clinicians, cross-checking medication interactions before signing off a prescription never gets old. Basic electronic health records flag risky combos, but nothing replaces looking at the actual patient in front of you, especially if they seem weary or confused. Granisetron hydrochloride tablets or injections work wonders for nausea, but in combination with new diagnoses like depression, heart trouble, or a round of antibiotics for a sinus infection, extra care protects the patient.
Facts matter, and safety does too. According to the FDA, reports of harmful interactions stay low, but every report reminds us not to skip the simple steps. If someone starts to feel weird after a medication change—whether dizzy, jittery, or with a skipped heartbeat—they should never ignore it. Early warning signs keep trouble small. Medicines do their best work when taken together wisely.
| Names | |
| Preferred IUPAC name | 1-methyl-1H-indazole-3-carboxylic acid, 7-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-, monohydrochloride |
| Other names |
Kytril Sancuso Granisetron HCl |
| Pronunciation | /ɡræˈnɪsɪtrɒn haɪˌdrɒklaɪd/ |
| Identifiers | |
| CAS Number | 107007-99-8 |
| Beilstein Reference | 5734448 |
| ChEBI | CHEBI:135409 |
| ChEMBL | CHEMBL1219 |
| ChemSpider | 122941 |
| DrugBank | DB00876 |
| ECHA InfoCard | 03cb70e7-6d3c-46c8-88a7-3348aacdb5c6 |
| EC Number | 602-866-5 |
| Gmelin Reference | 7248447 |
| KEGG | D08060 |
| MeSH | Dolasetron; Granisetron; Piperazines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists |
| PubChem CID | 149652 |
| RTECS number | GV7966600 |
| UNII | 5UX1YNN650 |
| UN number | UN3077 |
| CompTox Dashboard (EPA) | DTXSID8046857 |
| Properties | |
| Chemical formula | C18H25ClN4O |
| Molar mass | 348.22 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 0.8 g/cm3 |
| Solubility in water | Freely soluble in water |
| log P | 2.6 |
| Acidity (pKa) | 9.4 |
| Basicity (pKb) | 7.47 |
| Magnetic susceptibility (χ) | -74.5×10^-6 cm³/mol |
| Dipole moment | 2.23 D |
| Pharmacology | |
| ATC code | A04AA13 |
| Hazards | |
| Main hazards | May cause respiratory tract irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| Flash point | > 239.2 °C |
| Lethal dose or concentration | Lethal dose or concentration (LD50): Mouse (oral): 76 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse (oral): 76 mg/kg |
| NIOSH | GX8228000 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 2 mg |
| IDLH (Immediate danger) | NIOSH: Not Listed |
| Related compounds | |
| Related compounds |
Granisetron Tropisetron Ondansetron Dolasetron Palonosetron Alosetron Ramosetron |
